Relapsed or Refractory B-cell Lymphoma
10
1
1
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
10.0%
1 terminated out of 10 trials
0.0%
-86.6% vs benchmark
20%
2 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (10)
Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma
Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL
JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma
A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma
Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma
Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma
CART-19 Cells for R/R B-cell Lymphoma
Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma